Skip to main
TRAX

TRAX Stock Forecast & Price Target

TRAX Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 33%
Buy 67%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

First Tracks is in a strong financial position, with sufficient funding to support its pipeline development and continued research efforts. The company's focus on delivering immunology therapeutics for multiple autoimmune and inflammatory diseases positions it well for long-term success in the biotech market. Its strategic partnerships with pharmaceutical companies also provide opportunities for future growth and advancements in therapeutic development.

Bears say

First Tracks is at a high risk of not being able to bring its immunology therapeutics to market due to its reliance on external contractors for manufacturing, as any delay in their activity could significantly delay development timelines. Additionally, while their lead asset ANB033 has shown potential in its Phase 1a trial, the lack of ongoing trials in EoE for therapies with similar mechanisms of action raises concerns about the market opportunity and potential competition in this indication. Further validation of ANB033's mechanism of action through competitor readouts may be a key stock-moving event, but overall the company's early stage of development and lack of data in key indications increase the financial risks associated with investing in this stock.

TRAX has been analyzed by 6 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 67% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of First Tracks Biotherapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About First Tracks Biotherapeutics Inc (TRAX) Forecast

Analysts have given TRAX a Buy based on their latest research and market trends.

According to 6 analysts, TRAX has a Buy consensus rating as of May 6, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $41, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $41, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

First Tracks Biotherapeutics Inc (TRAX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.